Ads
related to: interstitial lung disease- Sign Up To Learn More
Receive Helpful Info
And Educational Resources Today.
- What Is NTM Lung Disease
Learn About NTM Lung Disease
That Is Caused By NTM Bacteria
- Lung Damage Visualizer
See How Untreated MAC Can
Damage The Lungs. Learn More.
- NTM Lung Visualizer
Learn How MAC Can Damage The Lungs.
See Inside The Lung Damage.
- Sign Up To Learn More
Search results
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
Zacks via Yahoo Finance· 19 hours agoAstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival...
Plainville woman successfully undergoes rare double lung transplant
The Sun Chronicle· 3 days ago“The cough turned out to be pneumonia, which led to her diagnosis of COP, or cryptogenic organizing...
AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative...
The Longview News-Journal· 2 days agoNew safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a next-generation, potential best-in-class c-Met directed ...
COVID patients at higher risk for respiratory complications well after infection, study finds
Center for Infectious Disease Research and Policy· 2 days agoThe risks of respiratory complications were eightfold and nearly twofold greater in COVID-19...
Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners
Zacks via Yahoo Finance· 6 days agoPresently, the portfolio includes Afirma (for thyroid cancer), Decipher Prostate (prostate cancer),...
AstraZeneca and Daiichi Sankyo’s ADC improves survival in NSCLC trial
Clinical Trials Arena via Yahoo Finance· 3 days agoDatopotamab deruxtecan’s safety profile was found to be in line with previous analyses, showing...
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Benzinga via Yahoo Finance· 2 days agoOn Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the...
AstraZeneca-Daiichi's Enhertu follow-up Dato-DXd unable to prove overall survival benefit in phase 3
FierceBiotech· 2 days agoDaiichi Sankyo and antibody-drug conjugate (ADC) partner AstraZeneca have already filed their...
J&J plans for capped, flexible dosing after four patient deaths in early study of actinium prostate...
Endpoints News· 7 days agoThe therapy resulted in five cases of interstitial lung disease, which is inflammation and scarring in the lung, and two of those cases ...
ASCO: J&J's radioligand spurs responses, but 4 deaths mar early results
FierceBiotech· 6 days agoJohnson & Johnson’s radiopharmaceutical spurred “profound and durable” responses, however, four...
